DDrare: Database of Drug Development for Rare Diseases

Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-AV-1451; 18F-FDG; 18F-RO6958948; 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione; AB1010; ABBV-8E12; AL; AL-108; ASK Nr. 21972; AZP2006 oral solution; Alpha-lipoic acid and L-acetyl carnitine; Anti-Parkinson medication; Antisense oligonucleotide; Azilect; BIIB092; BMS-986168; BMS986168; BOTULINUM TOXIN TYPE A; Balance; Bepranemab; Botulinum toxin type A; Carnitine; CoQ10; Coenzym Q10 Nanodispersion; Coenzym Q10, Ubiquinon, Ubichinon; Coenzyme Q10; Creatine; DaTSCAN™ Ioflupane (123I) Injection; DaTscan; Datscan; Davunetide; Davunetide (AL-108, NAP); Device: Deep Brain Stimulation; Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: [18F]-RO6958948; Donepezil; Droxidopa; Emeramide; Exelon 1,5 mg Hartkapseln; Exelon 3,0 mg Hartkapseln; Exelon 6,0 mg Hartkapseln; F-18; F-18 AV 1451; Flortaucipir; Flortaucipir F18; Flutemetamol; Flutemetamol F18; Fresh Frozen Plasma; GDNF & Synchro Med Infusion System; Gold; Hydrogen; Leucine; Lipoic acid; Lithium; MASITINIB MESYLATE; Masitinib; Masitinib 100mg; Masitinib 200mg; Masitinib mesylate; N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE; NBMI; NP031112; NP031112 600mg; NP031112 800mg; NT 101; Niacinamide; Nitrogen; Other: 13C6 Leucine; Placebo; Procedure: Brain PET scan; Pyruvate, creatine, niacinamide; RASAGILINE MESILATE; RIVASTIGMINE; Raclopride; Radiopharmaceuticals; Rasagilin; Rasagiline; Riluzole; Rivastigmine; Salsalate; Single dose C2N-8E12; Stem cell therapy; Sugar pill; Suvorexant; TPI 287 2 mg/m2; TPI-287 20 mg/m2; TPI-287 6.3 mg/m2; Tideglusib; Tolfenamic Acid; Tolfenamic acid; Trihexyphenidyl; UCB0107 (bepranemab); Ubidecarenon; Valproic acid; Vizamyl; Vizamyl (flutemetamol(F-18)); Water; Xeomin; Zolpidem; [18F]Florbetapir; [18F]MNI-815 (MNI-815); [18F]MNI-952; [18F]MNI-958; [18F]T807 ([18F]MNI-777); [F18]-FDDNP

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-001590-16-DE (EUCTR)	02/07/2019	11/01/2019	An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)	An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)	Progressive Supranuclear Palsy (PSP) MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-8E12 Other descriptive name: ABBV-8E12 Product Code: ABBV-8E12 Other descriptive name: ABBV-8E12	AbbVie Deutschland	NULL	Not Recruiting			Female: yes Male: yes	330	Phase 2	United States;Canada;Australia;Germany
2	EUCTR2016-001635-12-ES (EUCTR)	04/07/2018	10/05/2018	A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.	A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy	Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-8E12 INN or Proposed INN: ABBV-8E12 Other descriptive name: ABBV-8E12 Product Code: ABBV-8E12 INN or Proposed INN: ABBV-8E12 Other descriptive name: ABBV-8E12	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	330	Phase 2	United States;Canada;Spain;Australia;Germany;Italy
3	EUCTR2017-001590-16-IT (EUCTR)	27/04/2018	04/11/2020	An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)	An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) - na	Progressive Supranuclear Palsy (PSP) MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: na Product Code: ABBV-8E12 INN or Proposed INN: ABBV-8E12	ABBVIE DEUTSCHLAND GMBH & CO. KG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 2	United States;Canada;Australia;Germany;Italy
4	NCT03413319 (ClinicalTrials.gov)	April 17, 2018	23/1/2018	Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104	Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104	Progressive Supranuclear Palsy (PSP)	Drug: ABBV-8E12	AbbVie	NULL	Completed	18 Years	N/A	All	3	Phase 1	United States
5	NCT03391765 (ClinicalTrials.gov)	January 24, 2018	2/1/2018	An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)	An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)	Progressive Supranuclear Palsy (PSP)	Drug: ABBV-8E12	AbbVie	NULL	Completed	40 Years	N/A	All	143	Phase 2	United States;Australia;Canada;Italy;Japan;France
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	EUCTR2016-001635-12-DE (EUCTR)	23/11/2017	20/02/2017	A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.	A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy	Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-8E12 Product Code: ABBV-8E12 Other descriptive name: ABBV-8E12	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	330	Phase 2	United States;Canada;Spain;Australia;Germany;Italy
7	EUCTR2016-001635-12-FR (EUCTR)	26/10/2017	17/07/2017	A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.	A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy	Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-8E12	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 2	United States;France;Canada;Spain;Australia;Germany;Italy
8	EUCTR2016-001635-12-IT (EUCTR)	31/05/2017	05/02/2018	A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.	A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy - NA	Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ABBV-8E12 Product Code: ABBV-8E12 INN or Proposed INN: ABBV-8E12	ABBVIE DEUTSCHLAND GMBH & CO. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	180	Phase 2	United States;Canada;Australia;Italy
9	NCT02985879 (ClinicalTrials.gov)	December 12, 2016	1/12/2016	A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP).	A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy	Progressive Supranuclear Palsy	Drug: placebo;Drug: ABBV-8E12	AbbVie	NULL	Completed	40 Years	N/A	All	378	Phase 2	United States;Australia;Canada;France;Germany;Italy;Japan;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2017-001590-16-DE
(EUCTR)

02/07/2019

11/01/2019

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy (PSP)
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: ABBV-8E12
Other descriptive name: ABBV-8E12
Product Code: ABBV-8E12
Other descriptive name: ABBV-8E12

AbbVie Deutschland

NULL

Not Recruiting

Female: yes
Male: yes

330

Phase 2

United States;Canada;Australia;Germany

EUCTR2016-001635-12-ES
(EUCTR)

04/07/2018

10/05/2018

A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy

Progressive Supranuclear Palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
Other descriptive name: ABBV-8E12
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
Other descriptive name: ABBV-8E12

AbbVie Deutschland GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

330

Phase 2

United States;Canada;Spain;Australia;Germany;Italy

EUCTR2017-001590-16-IT
(EUCTR)

27/04/2018

04/11/2020

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) - na

Progressive Supranuclear Palsy (PSP)
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: na
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12

ABBVIE DEUTSCHLAND GMBH & CO. KG

NULL

Not Recruiting

Female: yes
Male: yes

180

Phase 2

United States;Canada;Australia;Germany;Italy

NCT03413319
(ClinicalTrials.gov)

April 17, 2018

23/1/2018

Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

Progressive Supranuclear Palsy (PSP)

Drug: ABBV-8E12

AbbVie

NULL

Completed

18 Years

N/A

All

Phase 1

United States

NCT03391765
(ClinicalTrials.gov)

January 24, 2018

2/1/2018

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy (PSP)

Drug: ABBV-8E12

AbbVie

NULL

Completed

40 Years

N/A

All

143

Phase 2

United States;Australia;Canada;Italy;Japan;France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2016-001635-12-DE
(EUCTR)

23/11/2017

20/02/2017

A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy

Product Code: ABBV-8E12
Product Code: ABBV-8E12
Other descriptive name: ABBV-8E12

AbbVie Deutschland GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

330

Phase 2

United States;Canada;Spain;Australia;Germany;Italy

EUCTR2016-001635-12-FR
(EUCTR)

26/10/2017

17/07/2017

A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy

Product Code: ABBV-8E12

AbbVie Deutschland GmbH & Co. KG

NULL

Not Recruiting

Female: yes
Male: yes

180

Phase 2

United States;France;Canada;Spain;Australia;Germany;Italy

EUCTR2016-001635-12-IT
(EUCTR)

31/05/2017

05/02/2018

A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy - NA

Product Name: ABBV-8E12
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12

ABBVIE DEUTSCHLAND GMBH & CO. KG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

180

Phase 2

United States;Canada;Australia;Italy

NCT02985879
(ClinicalTrials.gov)

December 12, 2016

1/12/2016

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP).

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy

Progressive Supranuclear Palsy

Drug: placebo;Drug: ABBV-8E12

AbbVie

NULL

Completed

40 Years

N/A

All

378

Phase 2

United States;Australia;Canada;France;Germany;Italy;Japan;Spain